C‐4 Modified Sialosides Enhance Binding to Siglec‐2 (CD22): Towards Potent Siglec Inhibitors for Immunoglycotherapy

Abstract

Two changes for the better: A novel class of sialic acid derivatives is prepared by modifying both the C-4 and C-9 positions of Neu5Aα2Me (see structure). This approach gives a lead compound that has sub-micromolar affinity for Siglec-2 and may provide a pathway for immunoglycotherapy strategies for autoimmune diseases and B cell derived non-Hodgkin's lymphoma. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.